Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2024

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Show Description +

Aamir Aziz, MD, summarizes the 2-year real-world efficacy and safety data for faricimab (Vabysmo, Genentech/Roche) in the setting of wet AMD.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

faricimab

•

Genentech

•

Roche

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

Up Next

Addressing the AMD Epidemic

Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA

Managing Concurrent Wet AMD and GA

Ted Leng, MD

A Look at Three-Year Data for Pegcetacoplan

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

The Latest Data on Photobiomodulation

The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision

A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

Optogenetics for RP: 12-Month Data

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President

SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Back to All Videos

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Aamir Aziz, MD, summarizes the 2-year real-world efficacy and safety data for faricimab (Vabysmo, Genentech/Roche) in the setting of wet AMD.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

faricimab

•

Genentech

•

Roche

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

Please log in to leave a comment.

More From ARVO: 2024 Coverage

Optogenetics for RP: 12-Month Data

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2024.